Abstract
The nitric oxide (NO) donor sodium nitroprusside (SNP) may promote cyanide-induced toxicity and systemic and/or local responses approaching maximal vasodilation. The hypotheses were tested that SNP superfusion of the rat spinotrapezius muscle exerts 1) residual impairments in resting and contracting blood flow, oxygen utilization ( 2 O V  ) and microvascular O 2 pressure (PO 2 mv); and 2) marked hypotension and elevation in resting PO 2 mv. Two superfusion protocols were performed: 1) Krebs-Henseleit (control 1), SNP (300 µM; a dose used commonly in superfusion studies) and Krebs-Henseleit (control 2), in this order; 2) 300 and 1200 µM SNP in random order. Spinotrapezius muscle blood flow (radiolabeled microspheres), 2 O V  (Fick calculation) and PO 2 mv (phosphorescence quenching) were determined at rest and during electrically-induced (1 Hz) contractions. There were no differences in spinotrapezius blood flow, 2 O V  or PO 2 mv at rest and during contractions pre-and post-SNP condition (control 1 and control 2; p>0.05 for all). With regard to dosing, SNP produced a graded elevation in resting PO 2 mv (p<0.05) with a reduction in mean arterial pressure only at the higher concentration (p<0.05).
Contrary to our hypothesis, skeletal muscle superfusion with the NO donor SNP (300 µM) improved microvascular oxygenation during the transition from rest to contractions (PO 2 mv kinetics) without precipitating residual impairment of muscle hemodynamic or metabolic control or compromising systemic hemodynamics. These data suggest that SNP superfusion (300 µM) constitutes a valid and important tool for assessing the functional roles of NO in resting and contracting skeletal muscle function without incurring residual alterations consistent with cyanide accumulation and poisoning.
Introduction
Nitric oxide (NO) and its derivatives are important modulators of skeletal muscle hemodynamic and metabolic control (Stamler and Meissner, 2001) . During the transition from rest to contractions, NO contributes to the increase in skeletal muscle oxygen delivery (
mainly via endothelium-dependent vasodilation (Hirai et al., 1994; Schrage et al., 2004 ) and the inertia of oxidative metabolism (i.e., finite 2 O V  kinetics) via inhibition of mitochondrial respiration (Jones et al., 2003; Kindig et al., 2002) . Accordingly, alterations in NO levels within skeletal muscle impact profoundly the dynamic 2 O Q  / 2 O V  matching (and thus the O 2 pressure within the microvasculature; PO 2 mv) during metabolic transitions in health and disease Ferreira et al., 2006b; Hirai et al., 2012; Hirai et al., 2010) . Pharmacological agents that release NO therefore represent valuable research tools for assessing the mechanistic roles of NO in physiology and pathophysiology (Ignarro et al., 2002) .
The NO donor sodium nitroprusside (SNP; sodium pentacyanonitrosylferrate, Na 2 [Fe(CN) 5 (NO)]) is a potent vasodilator used widely in both clinical and research arenas (human and animal models; Friederich and Butterworth, 1995; Ignarro et al., 2002) . SNP has rapid onset and reversibility of action and produces vasodilatory effects that resemble closely those of endogenous, endothelium-derived NO (Miller et al., 2004; Wanstall et al., 2001 ).
However, because SNP metabolism releases cyanide and may promote oxidative stress, its usage carries the risk of toxicity with prolonged administration and/or high dosages (Friederich and Butterworth, 1995; Ignarro et al., 2002; Pettersen and Cohen, 1993; Rao et al., 1991; Rauhala et al., 1998) . Specifically, cyanide-induced toxicity is associated with inhibition of mitochondrial oxidative phosphorylation (Pettersen and Cohen, 1993; Way, 1984) and impairments in vasomotor control (and consequently blood flow and/or mean arterial pressure regulation; Ignarro et al., 1986) which are expected to result in
These concerns led to reports recommending SNP usage to be curtailed or even discontinued (Rauhala et al., 1998; Robin and McCauley, 1992; Varon and Marik, 2003) and the Food and Drug Administration (FDA) approving a label for clinical SNP usage in 1991 that highlights its potential toxicity due to cyanide accumulation (Nightingale, 1991) .
The purpose of the present investigation was to determine whether SNP superfusion disrupts the functional integrity of skeletal muscle hemodynamic and/or metabolic control at rest and during contractions. It was hypothesized that skeletal muscle superfusion with SNP (300 µM, a concentration of the order employed in our and other laboratories; Behnke and Delp, 2010; Boegehold, 1992; Didion and Mayhan, 1997; Ferreira et al., 2006a; Ferreira et al., 2006b; Hirai et al., 2012; Hirai et al., 2010; Lash and Bohlen, 1997; Muller-Delp et al., 2002; Saito et al., 1994; Sato et al., 2008; Trott et al., 2009) reports from our laboratory demonstrate that these surgical procedures do not impair the microvascular integrity and responsiveness of the rat spinotrapezius muscle (Bailey et al., 2000) .
Experimental protocols
Rats were assigned randomly to different groups to examine whether the SNP superfusion concentration of the order employed in our and other laboratories (300 µM; Behnke and Delp, 2010; Boegehold, 1992; Didion and Mayhan, 1997; Ferreira et al., 2006a; Hirai et al., 2012; Hirai et al., 2010; Lash and Bohlen, 1997; Muller-Delp et al., 2002; Saito et al., 1994; Sato et al., 2008; Trott et al., 2009 ) evokes residual impairments in skeletal muscle hemodynamic and/or metabolic function (Group A; n=15) or responses consistent with maximal vasodilation (Group B; n=12). Chemicals and drugs were purchased from Sigma-Aldrich (St. Louis, MO, USA) and concentrations were chosen based on previous investigations from our and other laboratories (Behnke and Delp, 2010; Boegehold, 1992; Didion and Mayhan, 1997; Ferreira et al., 2006a; Ferreira et al., 2006b; Hirai et al., 2012; Hirai et al., 2010; Lash and Bohlen, 1997; Muller-Delp et al., 2002; Sato et al., 2008; Trott et al., 2009) . Specifically, the 300 µM SNP superfusion concentration was titrated to evoke consistent alterations in PO 2 mv without compromising systemic hemodynamics (i.e., a decrease in MAP below 70 mmHg at any time; Behnke et al., 2006; Ferreira et al., 2006b ). All solutions were kept at ~38°C. In order to minimize SNP photodecomposition and potential cyanide release (Bisset et al., 1981; Butler et al., 1987) , SNP solutions were protected from light sources by covering containers and syringes with aluminum foil and, as a mandate for PO 2 mv measurements using phosphorescence quenching, performing experiments in a darkened room.
Group A. Three contraction bouts were performed to examine potential impairment of spinotrapezius muscle hemodynamic and metabolic function with the relevant SNP superfusion (300 µM; see Fig. 1 ). The left and right spinotrapezius muscles were superfused in the following order: control 1 (5 ml Krebs-Henseleit), SNP (5 ml of a 300 µM SNP solution), control 2 (5 ml Krebs-Henseleit). Muscles were superfused with each solution (average flow rate of ~1.5 ml/min) for a total time of 3 min, followed by a 3 min incubation period (i.e., no superfusion) to allow resting MAP and muscle PO 2 mv to stabilize. Subsequently, electrical stimulation (1 Hz, ~7
V, 2 ms pulse duration) of the right spinotrapezius muscle was evoked via a Grass stimulator (model s48, Quincy, MA, USA) for 3 min and an ~20 min recovery period was undertaken before the next condition was initiated (stimulation parameters held constant). This stimulation protocol evokes an ~4-5 fold increase in blood flow along with ~6-7 fold increase in metabolic rate (i.e., ~30% of maximum spinotrapezius 2 O V  ) above resting with either minor or no changes in blood pH consonant with moderate intensity exercise (current results and Behnke et al., 2002; Behnke et al., 2001) . During the recovery period following the SNP condition, the left and right spinotrapezius muscles were superfused at an average flow rate of ~1.5 ml/min with KrebsHenseleit to washout SNP. This experimental design is deemed appropriate to examine potential impairments in skeletal muscle hemodynamic and metabolic function following SNP superfusion given that the current washout procedure is not expected to reverse any effects of cyanideinduced toxicity with SNP (Reade et al., 2012; Way, 1984) . Spinotrapezius muscle PO 2 mv was measured at rest and throughout contractions during all superfusion conditions. Spinotrapezius reproducible PO 2 mv profiles from three contraction bouts each separated by ~30 min (i.e., 3 min off-transition, ~20 min recovery, 3 min superfusion, 3 min incubation) with no ordering effects .
Group B. Two distinct superfusion protocols were performed to investigate whether the relevant SNP superfusion (300 µM) evokes responses consistent with or approximating maximal vasodilation (i.e., marked hypotension and elevation in resting PO 2 mv; see Fig. 1 ). The right spinotrapezius muscle was superfused in random order (5 ml of a 300 or 1200 µM SNP solution;
average flow rate of ~1.5 ml/min) for a total time of 3 min, followed by a 3 min incubation period (i.e., no superfusion) to allow resting MAP and muscle PO 2 mv to stabilize. These variables were measured and recorded and, before the second condition was initiated, the muscle was superfused for ~20 min at an average flow rate of ~1.5 ml/min with Krebs-Henseleit to wash out SNP. At the end of each experiment, rats were euthanized with intra-arterial pentobarbital sodium overdose (~50 mg/kg).
Measurement of blood flow
During blood flow measurements, the tail artery catheter was connected to a 1 ml syringe and blood withdrawal was initiated at a constant rate of 0.25 ml/min via a pump (model 907, Harvard Apparatus, Holliston, MA, USA). Differentially radiolabeled microspheres (   57   Co and   85 Sr, 15 µm diameter; Perkin Elmer Life and Analytical Sciences, Waltham, MA, USA) were injected in random order into the aortic arch via the carotid artery catheter during the contracting steady-state (i.e., ~3 min after the onset of muscle contractions). Upon completion of the experiment and immediately after euthanasia, the left and right spinotrapezius muscles, individual muscles or muscle parts of the hindlimb, kidneys and organs of the splanchnic region (adrenals, stomach, spleen, pancreas, small intestine, large intestine, liver) were dissected, removed and weighed. The thorax was opened and placement of the arterial catheter into the aortic arch was confirmed. Tissue radioactivity was determined on a gamma scintillation counter (Packard Auto Gamma Spectrometer, Cobra model 5003, Downers Grove, IL, USA) and blood flow was determined by the reference method (Ishise et al., 1980) and expressed as ml/min/100 g tissue. Adequate mixing of the microspheres was verified for each injection by the demonstration of a <15% difference in blood flow between the left and right kidneys.
Measurement of muscle PO 2 mv
Spinotrapezius PO 2 mv was measured by phosphorescence quenching using a Frequency Domain Phosphorometer (PMOD 5000; Oxygen Enterprises, Philadelphia, PA, USA). The principles of the phosphorescence quenching technique have been described in detail previously (Behnke et al., 2001) . Briefly, this technique applies the Stern-Volmer relationship (Rumsey et al., 1988) which describes quantitatively the O 2 dependence of phosphorescent probe (R2) via the following equation: at pH = 7.4 and temperature ~38°C) (Lo et al., 1997) was infused ~15 min prior to muscle contractions. The R2 probe binds to albumin and is distributed uniformly in the plasma, thus providing a signal corresponding to the volume-weighted O 2 pressure in the microvascular compartment (primarily the PO 2 within the capillaries, which volumetrically represents the major intramuscular space; Poole et al., 2004) . The negative charge of the R2 probe also facilitates its restriction to the muscle intravascular space (Poole et al., 1995) . The common end of the bifurcated light guide was placed 2-4 mm superficial to the dorsal surface of the exposed right spinotrapezius muscle. The phosphorometer modulates sinusoidal excitation frequencies between 100 Hz and 20 kHz and allows phosphorescence lifetime measurements from approximately 10 µs to 2.5 ms. The excitation light (524 nm; penetration depth of ~500 µm) was focused on a randomly selected area of ~2 mm diameter of exposed muscle and PO 2 mv was recorded at 2 s intervals throughout the duration of the experimental protocol.
PO 2 mv kinetics analysis
The kinetics of PO 2 mv during the onset of contractions were described by nonlinear regression analysis using the Marquardt-Levenberg algorithm (SigmaPlot 11.2; Systat software, San Jose, CA, USA). Transient PO 2 mv responses were fit with either a one-or two-component model (Behnke et al., 2001 ):
One-component:
where PO 2 mv (t) is the PO 2 mv at a given time t, PO 2 mv (BL) corresponds to the pre-contracting resting PO 2 mv, Δ 1 and Δ 2 are the amplitudes for the first and second components, respectively, TD 1 and TD 2 are the independent time delays for each component, and τ 1 and τ 2 are the time constants (i.e., time taken to achieve 63% of the response) for each component. Goodness of fit was determined using three criteria: 1) the coefficient of determination; 2) the sum of squared residuals; and 3) visual inspection.
The mean response time (MRT; Macdonald et al., 1997) was used to describe the overall dynamics of the PO 2 mv fall:
where TD 1 and τ 1 are defined above. The MRT analysis was limited to the first component of the PO 2 mv response given that inclusion of an emergent second component underestimates the actual speed of PO 2 mv fall following the onset of contractions (Hirai et al., 2009 ).
The area under the PO 2 mv curve plotted as function of time (PO 2Area ; Hirai et al., 2010) was calculated throughout each 3 min contraction protocol to provide an index of the overall spinotrapezius muscle microvascular oxygenation (i.e., incorporating resting and contracting steady-state PO 2 mv, time delays, time constants and amplitudes of the response to yield a value expressed as mmHg . s).
Calculation of muscle
O V  was estimated from PO 2 mv and blood flow measurements as described in detail previously . Briefly, arterial O 2 concentration (CaO 2 ) was calculated from arterial blood samples whereas venous O 2 concentration (CvO 2 ) was calculated from the resting or contracting steady-state spinotrapezius PO 2 mv using the rat O 2 dissociation curve (Hill coefficient of 2.6), the measured hemoglobin (Hb) concentration, a P 50 of 38 mmHg, and an O 2 carrying capacity of 1.34 ml O 2 /g Hb (Altman and Dittmer, 1974 Fig. 2) . Importantly, there were no differences in these responses at rest and during contractions when comparing control 1 and post-washout control 2 (p>0.05 for all; Fig. 2 ).
SNP elevated resting and contracting steady-state PO 2 mv (PO 2 mv (BL) and PO 2 mv (SS) , respectively; p<0.05 for both; Fig. 3 and Table 1 ). No differences in the amplitudes and time delays of the PO 2 mv response were observed among conditions (p>0.05 for all; Table 1 ). The speed of PO 2 mv fall at the onset of contractions (as assessed by the time constant for the primary component (τ 1 ), mean response time (MRT), time to reach 63% of the primary amplitude (T 63 ) and relative rate of PO 2 mv fall (Δ 1 PO 2 mv/τ 1 )) was markedly slowed in the SNP condition when compared to both control 1 and post-washout control 2 (p<0.05 for all; Table 1 ). As a result, SNP elevated the overall muscle microvascular oxygenation throughout contractions (PO 2AREA ) when compared to both control 1 and control 2 conditions (p<0.05; Table 1 ). Importantly, there were no differences in the PO 2 mv responses during the transition from rest to contractions when comparing control 1 and control 2 (p>0.05 for all kinetics parameters; Table 1 ).
There were no differences in total resting hindlimb muscle blood flow before and after superfusion of the spinotrapezius muscle with 300 µM SNP (control 1: 7 ± 1; control 2: 8 ± 1 ml/min/100 g, respectively, p>0.05). Accordingly, 27 of 28 individual hindlimb muscles or muscle parts had similar blood flow when comparing control 1 and control 2 (exception: red gastrocnemius; Table 2 ). Similar blood flows to the kidneys and the majority of organs of the splanchnic region (exception: pancreas; Table 3 ) were observed when comparing control 1 and control 2.
Group B: Systemic and local effects of distinct SNP superfusion concentrations (300 and 1200 µM).
Pre-SNP superfusion MAP and spinotrapezius PO 2 mv were not different between 300
and 1200 µM conditions (p>0.05 for both; Fig. 4 ). Spinotrapezius superfusion with 300 µM SNP did not reduce MAP (p>0.05) and elevated resting PO 2 mv by ~30% (p<0.05; Fig. 4 ).
Spinotrapezius superfusion with 1200 µM reduced MAP by ~33% (p<0.05) and increased resting PO 2 mv to a greater extent (~88%) compared to the 300 µM SNP concentration (p<0.05; Fig. 4) .
Accordingly, the changes in MAP and resting PO 2 mv with 1200 µM SNP were greater than those observed with 300 µM SNP (p<0.05 for both; Fig. 4 ).
Discussion
Contrary to our principal hypothesis, the present investigation demonstrates that acute superfusion of the rat spinotrapezius with 300 µM SNP does not precipitate residual impairment of muscle hemodynamic or metabolic control either at rest or during contractions. Improved spinotrapezius muscle microvascular oxygenation during the rest-contraction transient (PO 2 mv kinetics) seen herein during the SNP bout (300 µM) is consistent with that reported previously Ferreira et al., 2006b; Hirai et al., 2012; Hirai et al., 2010) . Importantly, there were no differences in skeletal muscle blood flow, 
SNP and skeletal muscle function
SNP-induced toxicity is considered to arise primarily from cyanide release and accumulation as a product of its metabolism (Friederich and Butterworth, 1995; Ignarro et al., 2002; Pettersen and Cohen, 1993; Rao et al., 1991) . Cyanide inhibits mitochondrial oxidative phosphorylation and is thus expected to lower both resting and contracting muscle Pettersen and Cohen, 1993) . In addition, cyanide accumulation may rapidly and irreversibly impair vasomotor control and consequently alter resting and contracting muscle blood flow (Ignarro et al., 1986) . Consistent with these notions, cyanide poisoning is often used experimentally to inhibit mitochondrial respiration at cytochrome c oxidase (i.e., uncoupling agent; Shen et al., 1995; Shiva et al., 2007) and abolish vascular smooth muscle tone (e.g., Levy et al., 1993; Marano et al., 1999) . These alterations, alone or in combination, are expected to disrupt the dynamic matching between muscle blood flow and and/or irreversible vasodilation secondary to SNP-induced toxicity (Ignarro et al., 1986) is not supported based on the lack of differences in resting and contracting muscle blood flow between the first and third bouts (i.e., control 1 and control 2, respectively; Fig. 2 ). In addition, similar spinotrapezius PO 2 mv kinetics parameters and temporal profiles during the first and third bouts (i.e., control 1 and control 2, respectively; Table 1 and Fig. 3 ) are consistent with the notion that muscle vascular and mitochondrial function were not impaired following SNP washout.
Similar resting blood flows to the total hindlimb musculature and vast majority (27 of 28) of individual muscles or muscle parts of the hindlimb during the first and third bouts (i.e., control 1 and control 2, respectively; Table 2 ) provide further evidence that superfusion of the spinotrapezius with 300 µM SNP did not induce systemic toxicity. This notion is also supported by the finding of similar blood flows to the kidneys and most organs of the splanchnic region when comparing control 1 and control 2 (the pancreas being the only exception; Table 3 ).
Taken together, these data suggest that superfusion of the spinotrapezius with 300 µM SNP does not impair skeletal muscle hemodynamic and metabolic function at rest or during contractions. The apparent absence of local and systemic toxicity with the 300 µM SNP superfusion concentration observed herein occurred despite whatever cyanide radicals may have been released as a product of SNP metabolism (Friederich and Butterworth, 1995; Ignarro et al., 2002; Rao et al., 1991; Rauhala et al., 1998) . As reviewed previously (Friederich and Butterworth, 1995; Way, 1984) , cyanide from SNP reacts mainly with methemoglobin to produce cyanomethemoglobin (which is in dynamic equilibrium with cyanide and nontoxic) or thiosulfate in the liver via the catalytic action of rhodanase to produce thiocyanate (which is excreted by the kidneys). Additional pathways of cyanide detoxification include reactions with cystine (Wood and Cooley, 1956 ) and those catalyzed by the enzyme mercaptopyruvate sulfurtransferase (Nagahara et al., 1999) , among others. Toxicity is therefore expected to occur principally: 1) with prolonged administration and/or high dosages of SNP which promote cyanide accumulation; and/or 2) in patients with some degree of renal and/or hepatic insufficiency (Friederich and Butterworth, 1995; Ignarro et al., 2002) . It might be anticipated that oxidative stress mediated by SNP occurs primarily under the former circumstances. Interestingly, the SNP label introduced by the FDA in 1991 is consistent with those notions and emphasizes the risk of cyanide toxicity due to inappropriate dosages and/or extended use (Nightingale, 1991) . It is important to note that the characteristics of the drug delivery method applied herein limit the potential toxic effects of cyanide accumulation from superfused SNP (see below).
It must also be acknowledged that 1) certain methods used for assaying blood cyanide concentration; and/or 2) SNP photodecomposition (which facilitates cyanide release) may overestimate the role of cyanide-induced toxicity with SNP and have promulgated the notion of SNP toxicity (Bisset et al., 1981; Butler et al., 1987) . These aspects must be considered when utilizing the NO donor SNP in both clinical and research settings and may account, at least in part, for the controversy regarding SNP safety and reliability (Friederich and Butterworth, 1995) .
Thus, the lack of residual impairments in skeletal muscle function following SNP treatment demonstrated herein (Figs. 2 and 3) is consistent with the fact that appropriate administration of the NO donor SNP intravenously represents a powerful tool in the standard drug treatment of hypertension and chronic heart failure without promoting vascular and/or metabolic dysfunction (Cohn et al., 2011; Dickstein et al., 2008; Friederich and Butterworth, 1995; Ignarro et al., 2002) .
It may be argued that other NO donors, such as diazeniumdiolates (e.g., spermine
NONOate), could be used in an attempt to circumvent potential SNP-induced toxicity. However, heterogeneities in vasodilatory properties of NO donors must be taken into account based on the purpose of a given investigation. Contrary to SNP, spermine NONOate releases NO extracellularly and induces vasodilation via a soluble guanylate cyclase-independent mechanism, which differs from that associated with endogenous, endothelium-derived NO (Miller et al., 2004; Wanstall et al., 2001) .
SNP superfusion concentrations
As noted above, the SNP superfusion concentration used herein (300 µM) is similar to that used by others (Behnke and Delp, 2010; Boegehold, 1992; Didion and Mayhan, 1997; Lash and Bohlen, 1997; Muller-Delp et al., 2002; Saito et al., 1994; Sato et al., 2008; Trott et al., 2009 ) and was established in previous investigations by titrating different doses and selecting carefully that one which elicited consistent alterations in muscle PO 2 mv without compromising systemic hemodynamics (i.e., MAP<70 mmHg at any time; Behnke et al., 2006; Ferreira et al., 2006b ). The 300 µM SNP concentration is therefore relatively higher than that used in intra-arterial infusions or isolated tissue incubation baths due to the nature of the drug delivery method (i.e., superfusion), in which 1) considerable resistance to diffusion exists inherently; and 2) superfused chemicals are only briefly in contact with the curved dorsum of the in situ spinotrapezius as gravity directs the fluid away from the muscle to be discarded.
Importantly, spinotrapezius superfusion with 300 µM SNP did not decrease MAP and elevated resting PO 2 mv to a lesser extent when compared to 1200 µM SNP (Fig. 4) . These data indicate that superfusion of the rat spinotrapezius muscle with 300 µM SNP increases resting PO 2 mv without evoking responses consistent with or approximating maximal vasodilation. The latter point is significant because it allows further vasodilation in response to muscle contractions or other mediators and does not abolish sympathetic neural control over vascular tone. As discussed previously Ferreira et al., 2006b; Hirai et al., 2010) , the very mild hypotensive response seen herein following SNP superfusion of the spinotrapezius muscle likely derives from 'leakage' of the superfusate from within the vicinity of the muscle into the systemic circulation.
Experimental considerations
Technical limitations related to the presence of radiolabeled microspheres precluded direct cyanide measurements in resting and contracting skeletal muscle. In addition, blood samples were not taken for cyanide measurements given that the superfusion method used herein, contrary to SNP infusion, is not expected to impact systemic cyanide levels appreciably.
Nonetheless, considering that SNP metabolism releases cyanide along with NO (Friederich and Butterworth, 1995) , one strength of the current investigation is evaluation of potential adverse effects of local SNP superfusion (300 µM) on resting and contracting skeletal muscle vascular and metabolic function in vivo (Group A).
Notwithstanding the synergistic and redundant nature of the multiple mechanisms regulating skeletal muscle blood flow, NO has been identified as an important component of the functional hyperemia response (e.g., Hirai et al., 1994; Schrage et al., 2004) . That NO is integral to skeletal muscle Hirai et al., 2010) , aged (Hirai et al., 2009) , disease and exercise trained states indicates that NO-mediated vascular and metabolic regulation in the rat spinotrapezius preparation is similar to those observed in the intact rat (Hirai et al., 1994) , horse (Kindig et al., 2002) and human (Jones et al., 2003; Schrage et al., 2004) .
Summary and conclusions
Utilization of NO donors such as SNP is pivotal in identifying the functional roles of NO in physiology and pathophysiology (Ignarro et al., 2002) . The current investigation demonstrates that superfusion of the rat spinotrapezius with 300 µM SNP does not impair skeletal muscle hemodynamic or metabolic function at rest or during contractions. Importantly, this SNP superfusion concentration elevates resting muscle PO 2 mv without compromising systemic hemodynamics (i.e., MAP<70 mmHg at any time; present results and Behnke et al., 2006; Ferreira et al., 2006b) or altering resting blood flow to the total hindlimb musculature. In addition, no differences in basal blood flow to the kidneys and majority of the organs of the splanchnic region were observed when comparing pre-and post-SNP conditions. Collectively, these observations indicate that SNP superfusion (300 µM) constitutes a valid and important tool for assessing the functional roles of NO in skeletal muscle hemodynamic and metabolic control at rest and during contractions without incurring residual alterations consistent with cyanide accumulation and poisoning. Gastrocnemius, mixed 8 ± 1 8 ± 1
Tables
Tibialis posterior 11 ± 4 14 ± 3
Flexor digitorum longus 7 ± 4 17 ± 5
Flexor halicus longus 7 ± 1 8 ± 1
Ankle flexors Tibialis anterior, red 8 ± 3 10 ± 1
Tibialis anterior, white 9 ± 2 9 ± 2
Extensor digitorum longus 9 ± 2 7 ± 1 Values are mean ± SE. *p<0.05 vs. control 1. Values are mean ± SE. *p<0.05 vs. control 1. †Designates arterial, not portal, blood flow and vascular conductance. PO 2 mv along with slower speed of PO 2 mv fall at contractions onset, see Table 1 ) and the similarity between control 1 and control 2 (p>0.05 for all kinetics parameters, see Table 1 ). Time zero denotes the onset of muscle contractions. See text for further details.
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